Symptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Hydrocodone | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Chlorprothixene can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Chlorprothixene may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Mirtazapine | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Orphenadrine | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Rotigotine | Chlorprothixene may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorprothixene. |
| Sodium oxybate | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Thalidomide | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Aclidinium | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Chlorprothixene. |
| Mirabegron | The risk or severity of urinary retention can be increased when Chlorprothixene is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Chlorprothixene is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Chlorprothixene. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Chlorprothixene. |
| Tiotropium | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Chlorprothixene is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Umeclidinium. |
| Amisulpride | Chlorprothixene may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorprothixene. |
| Sulpiride | Chlorprothixene may increase the antipsychotic activities of Sulpiride. |
| Benzylpenicilloyl polylysine | Chlorprothixene may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Chlorprothixene. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Chlorprothixene. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Chlorprothixene. |
| Mequitazine | Chlorprothixene may increase the arrhythmogenic activities of Mequitazine. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glycopyrronium. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with (S)-Warfarin. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum toxin type A. |
| Glucagon | Chlorprothixene may increase the gastrointestinal motility reducing activities of Glucagon. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Chlorprothixene is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Chlorprothixene is combined with Ramosetron. |
| Ethanol | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene. |
| Zimelidine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluvoxamine. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Chlorprothixene. |
| Indalpine | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alaproclate. |
| Amphetamine | Amphetamine may decrease the sedative activities of Chlorprothixene. |
| Phentermine | Phentermine may decrease the sedative activities of Chlorprothixene. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Chlorprothixene. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Chlorprothixene. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Chlorprothixene. |
| Lisdexamfetamine | Lisdexamfetamine may decrease the sedative activities of Chlorprothixene. |
| Mephentermine | Mephentermine may decrease the sedative activities of Chlorprothixene. |
| MMDA | MMDA may decrease the sedative activities of Chlorprothixene. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Chlorprothixene. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Chlorprothixene. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorprothixene. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Chlorprothixene. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Chlorprothixene. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Chlorprothixene. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Chlorprothixene. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Chlorprothixene. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Chlorprothixene. |
| Ritobegron | Ritobegron may decrease the sedative activities of Chlorprothixene. |